Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention

Annals of Internal Medicine

Volumn 131, Issue 9, 1999, Pages 688-695

  Hart, Robert G ^a   Halperin, Jonathan L ^b   Hudson, Barbara ^c  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b MOUNT SINAI MEDICAL CENTER   (United States)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN;

ANTICOAGULANT THERAPY; ARTICLE; DISEASE ASSOCIATION; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HUMAN; PRIORITY JOURNAL; RISK ASSESSMENT; STROKE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 0032730430     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-131-9-199911020-00010     Document Type: Article

References (80)

1. Friedman GD, Loveland DB, Ehrlich SP Relationship of stroke to other cardiovascular disease. Circulation. 1968;38:533-41.
2. Wolf PA, Dawber TR. Thomas HE It, Kännel WB. Epidemiologie assessment of chronic atrial fibrillation and risk of stroke: the Framingham study. Neurology. 1978:28:973-7.
3. Fisher CM. Reducing risks of cerebral embolism. Geriatrics. 1979;34:59-61, 65-6.
4. Hinton RC, Kistler IP. Fallon JT, Friedlich AL, Fisher CM. Influence of etiology of atrial fibrillation on incidence of systemic embolism. Am J Cardiol. 1977;40:509-13.
5. Feinberg WM, Blackshear JL, Laupacis A, Kronmal R, Hart RG. Prevalence, age distribution, and gender of patients with atrial fibrillation. Analysis and implications. Arch Intern Med. 1995;155:469-73.
6. Hart RG, Benavente O, McBride R, Pearce LA. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med. 1999:131:492-501.
7. Bleeding during antithrombotic therapy in patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. Arch Intern Med. 1996; 156:409-16.
8. Gorter JW. Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention in Reversible Ischemia (SPIRIT) and European Atrial Fibrillation Trial (EAFT) Study Groups. Neurology. [In press).
9. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med. 1994;120:897-902.
10. Finn SD, Callahan CM, Martin DC, McDonell MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med. 1996; 124:970-9.
11. Sudlow M, Thomson R, Thwaites B, Rodgers H, Kenny RA. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet. 1998:352:1167-71.
12. Hylek EM, Skates SJ, Sheehan MA, Singer DE. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med. 1996:335:540-6.
13. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomised clinical trial. Lancet. 1996:348:633-8.
14. Optimal oral anticoagulant therapy in patients with nonrheumatic atrial fibrillation and recent cerebral ischemia. The European Atrial Fibrillation Trial Study Group. N Engl J Med. 1995:333:5-10.
15. Hart RG. Intensity of anticoagulation to prevent stroke in patients with atrial fibrillation [Letter]. Ann Intern Med. 1998:128:408.
16. Ezekowitz MO, Bridgcrs SU James KE, Carliner NH, Colling CL. Gornick CC, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. Veterans Affairs Stroke Prevention in Nonrheumatic Atrial Fibrillation Investigators. N Engl J Med. 1992;327:1406-12.
17. The effect of low-dose warfarin on the risk of stroke in nonrheumatic atrial fibrillation. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. N Engl J Med. 1990:323:1505-11.
18. Minematsu K, Yasaka M, Yamaguchi T. Optimal intensity of warfarin therapy for secondary prevention of stroke in patients with nonvalvular atrial fibrillation: a prospective, randomized, multicenter trial [Abstract). Stroke. 1999:30:241.
19. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. The Atrial Fibrillation Investigators. Arch Intern Med. 1997:157:1237-40.
20. Miller VT. Rothrock JF. Pearce LA, Feinberg WM, Hart RG, Anderson DC. Ischémie stroke in patients with atrial fibrillation: effect of aspirin according to stroke mechanism. Stroke Prevention in Atrial Fibrillation Investigators. Neurology. 1993:43:32-6.
21. Hart RG, Pearce LA, Miller VT, Anderson DC Rothrock JF, Albers GW, et al. Cardioembolic vs. noncardioembolic strokes in atrial fibrillation: frequency and effect of antithrombotic agents. Cerebrovasc Dis. [In press).
22. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAFT (European Atrial Fibrillation Trial) Study Group. Lancet, 1993:342:1255-62.
23. Gullov AL, Koefoed BG, Petersen P, Pedersen TS, Anderson ED, Godtfredsen J, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med. 1998:158:1513-21.
24. Hellemons BS, Langenberg M, Lodder J, Vermeer F, Scheuten HJ, Lemmens T, et al. Primary prevention of arterial thromboembolism in patients with nonrheumatic atrial fibrillation in general practice (the PATAF study) [Abstract]. Cerebrovasc Dis. 1997;7(Suppl 4):11.
25. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation. Stroke Prevention in Atrial Fibrillation II Study. Lancet. 1994;343:687-91.
26. Hart RG, Benavente O, Pearce LA. Increased risk of intracranial hemorrhage when aspirin is combined with warfarin: a meta-analysis and hypothesis. Cerebrovasc Dis. 1999:9:215-7.
27. Kopecky SL, Gersh BJ, McGoon MD, Whisnant JP, Holmes DR Jr, llstrup DM, et al. The natural history of lone atrial fibrillation. A populationbased study over three decades. N Engl J Med. 1987:317:669-74.
28. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Analysis of pooled data from five randomized clinical trials. Arch Intern Med. 1994:154:1449-57.
29. Hart RG, Pearce LA, McBride R, Rothbart RM, Asinger RW. Factors associated with ischémie stroke during aspirin therapy in atrial fibrillation: analysis of 2012 participants in the SPAF Mil clinical trials. The Stroke Prevention in Atrial Fibrillation (SPAF) Investigators. Stroke. 1999:30:1223-9.
30. Predictors of thromboembolism in atrial fibrillation: I. Clinical features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992:116:1-5.
31. Predictors of thromboembolism in atrial fibrillation: II. Echocardiographic features of patients at risk. The Stroke Prevention in Atrial Fibrillation Investigators. Ann Intern Med. 1992:116:6-12.
32. Moulton AW, Singer DE, Haas JS. Risk factors for stroke in patients with nonrheumatic atrial fibrillation: a case-control study. Am J Med. 1991 ;91:156-61.
33. Flegel KM, Henley J. Risk factors for stroke and other embolie events in patients with nonrheumatic atrial fibrillation. Stroke. 1989:20:1000-4.
34. Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation Study. Stroke Prevention in Atrial Fibrillation Investigators. Journal of Stroke and Cerebrovascular Disease. 1995:5:147-57.
35. Aronow WS, Ahn C, Kronzon I, Gutstein H. Risk factors for new thromboembolic stroke in patients > or = 62 years of age with chronic atrial fibrillation. Am J Cardiol. 1998:82:119-21.
36. Stollberger C, Chnupa P, Kronik G, Brainin M, Finsterer J, Schneider B, et al. Transesophageal echocardiography to assess embolie risk in patients with atrial fibrillation. ELAT Study Group. Embolism in Left Atrial Thrombi. Ann Intern Med. 1998; 128:630-8.
37. Petersen P, Kastrup J, Helweg-Larsen S. Boysen G, Godtfredsen J. Risk factors for thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Arch Intern Med. 1990:150:819-21.
38. van Latum JC, Koudstaal PJ. Venables GS, van Gijn J, Kappelle U, Algra A. Predictors of major vascular events in patients with a transient ischémie attack or minor ischémie stroke and nonrheumatic atrial fibrillation. European Atrial Fibrillation Trial (EAFT) Study Group. Stroke. 1995:16:801-6.
39. Echocardiographic predictors of stroke in patients with atrial fibrillation: a prospective study of 1066 patients from 3 clinical trials. Arch Intern Med. 1998:158:1316-20.
40. Yoshida M, Nakamura Y, Higashikawa M, Kinoshita M. Predictors of ischémie stroke in non-rheumatic atrial fibrillation. Int J Cardiol. 1996;56:61-70.
41. Nakagami H, Yamamoto K, Ikeda U, Mitsuhashi T, Goto T. Shimada K. Mitral régurgitation reduces the risk of stroke in patients with nonrheumatic atrial fibrillation. Am Heart J. 1998:136:528-32.
42. Aronow WS, Gutstein H, Hsieh FY. Risk factors for thromboembolic stroke in elderly patients with chronic atrial fibrillation. Am J Cardiol. 1989;63:366-7.
43. Blackshear JL. Pearce LA, Asinger RW, Dittrich HC, Goldman ME, Zabalgoitia M, et al. Mitral régurgitation associated with reduced thromboembolic events in high-risk patients with nonrheumatic atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Am J Cardiol. 1993;72:840-3.
44. Zabalgoitia M. Halperin JL, Pearce LA, Blackshear JL, Asinger RW, Hart RG. Transesophageal echocardiographic correlates of clinical risk of thromboembolism in nonvalvular atrial fibrillation. Stroke Prevention in Atrial Fibrillation III Investigators. J Am Coll Cardiol. 1998;3l:1622-6.
45. Goldman ME, Pearce LA, Hart RG, Zabalgoitia M, Asinger RW, Safford R, et al. Pathophysiologic correlates of thromboembolism in nonvalvular atrial fibrillation: reduced flow velocity in the left atrial appendage. J Am Soc Echocardiogr. [In press).
46. Asinger RW, Koehler J, Pearce LA. Zabalgotia M, Blackshear JL, Fenster PE, et al. Pathophysiologic correlates in nonvalvular atrial fibrillation: Spontaneous echo-contrast. J Am Soc Echocardiogr. [In press).
47. Fröhlich ED, Apstein C, Chobanian AV, Devereux RB, Dustan HP, Dzau V, et al. The heart in hypertension. N Engl J Med. 1992:327:998-1008.
48. Schmeider RE, Martus P, Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA. 1996;275:1507-13.
49. A differential effect of aspirin for prevention of stroke in atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. J Stroke Cerebrovasc Dis. 1993,3:181-8.
50. Dittrich HC, Pearce LA, Asinger RW, McBride R. Webel R, Zabalgoitia M, et al. Left atrial diameter in nonvalvular atrial fibrillation: an echocardiographic study. Am Heart J. 1999:137:494-9.
51. Blackshear JL, Pearce LA, Hart RG, Zabalgoitia M, Labovitz A, Asinger RW, et al. Aortic plaque in atrial fibrillation: prevalence, predictors, and thromboembolic implications. Stroke. 1999;30:834-40.
52. Cushman M. Psaty BM, Macy E, Bovill EG, Cornell ES, Kuller LH, et al. Correlates of thrombin markers in an elderly cohort free of clinical cardiovascular disease. Arterioscler Thromb Vase Biol. 1996; 16:1163-9.
53. Feinberg WM. Cornell ES, Nightingale SD, Pearce LA, Tracy RP, Hart RG, et al. Relationship between prothrombin in activation fragment F1.2 and international normalized ratio in patients with atrial fibrillation. Stroke Prevention in Atrial Fibrillation Investigators. Stroke. 1997;28:1101-6.
54. Tsai LM, Lin U, Teng JK, Chen JH. Prevalence and clinical significance of left atrial thrombus in nonrheumatic atrial fibrillation. Int J Cardiol. 1997;58: 163-9.
55. Patients with nonvalvular atrial fibrillation at low risk of stroke during treatment with aspirin: Stroke Prevention in Atrial Fibrillation III Study. The SPAF III Writing Committee for the Stroke Prevention in Atrial Fibrillation Investigators. JAMA. 1998:279:1273-7.
56. Laupacis A, Albers G. Daten J, Dünn MI, Jacobsen AK, Singer DE. Antithrombotic therapy in atrial fibrillation. Chest. 1998;114(5 Suppl):579-895.
57. Feinberg WM. Kronmal RA, Newman AB, Kraut MA, Bovill EG, Cooper L, et al. Stroke risk in an elderly population with nonvalvular fibrillation. J Gen Intern Med. 1999; 14:56-9.
58. Hart RG, Pearce LA, Rothbart RL, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. J Am Coll Cardiol. [In press).
59. Kalra L, Perez I, Melbourn A. Risk assessment and anticoagulation for primary stroke prevention in atrial fibrillation. Stroke. 1999;30:1218-22.
60. Transesophageal echocardiographic correlates of thromboembolism in highrisk patients with atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators Committee on Echocardiography. Ann Intern Med. 1998; 128:639-47.
61. Corrado G, Tadeo G, Beretta S, Tagliagambe LM, Manzillo GF, Spata M, et al. Atrial thrombi resolution after prolonged anticoagulation in patients with atrial fibrillation. Chest. 1999; 115:140-3.
62. Manning WJ, Douglas PS. Transesophageal echocardiography and atrial fibrillation: added value or expensive toy? [Editorial] Ann Intern Med. 1998; 128:685-7.
63. Amarenco P, Cohen A, Tzourio C, Bertrand B. Hommel M, Besson G, et al. Atherosclerotic disease of the aortic arch and the risk of ischémie stroke. N Engl J Med. 1994;331:1474-9.
64. Amarenco P, Cohen A, Hommel M, Bousser M. Atherosclerotic disease of the aortic arch and the risk of ischémie stroke [Letter]. N Engl J Med. 1995; 332:1237-8.
65. Jones EF, Kaiman JM, Calafiore P, Tonkin AM, Donnan GA. Proximal aortic atheroma. An independent risk factor for cerebral ischemia. Stroke. 1995:26:218-24.
66. Davila-Roman VG, Murphy SF, Nickerson NJ, Kouchoukos NT, Schechtman KB, Barzilai B. Atherosclerosis of the ascending aorta is an independent predictor of long-term neurologic events and mortality. J Am Coll Cardiol. 1999;33:1308-16.
67. Ferrari E, Vidai R, Chevallier T, Baudouy M. Atherosclerosis of the thoracic aorta and aortic debris as a marker of poor prognosis: benefit of oral anticoagulants. J Am Coll Cardiol. 1999;33:1317-22.
68. Mitusch R, Lange V, Stierle U, Maurer B, Sheikhzadeh A. Transesophageal echocardiographic determinants of embolism in nonrheumatic atrial fibrillation. Int J Card Imaging. 1995:11:27-34.
69. Kahn SR, Solymoss S, Flegel KM. Increased tissue plasminogen activator levels in patients with nonvalvular atrial fibrillation. CMAJ. 1997; 157:685-9.
70. Pongratz G, Brandt-Pohlmann M, Henneke KH, Pohle C Zink D, Genling G. et al. Platelet activation in embolie and preembolic status of patients with nonrheumatic atrial fibrillation. Chest. 1997;111:929-33.
71. Sohara H, Amitani S, Kurose M, Miyahara K. Atrial fibrillation activates platelets and coagulation in a time-dependent manner: a study in patients with paroxysmalatrial fibrillation. J Am Coll Cardiol. 1997;29:106-12.
72. Asakura H, Hifumi S, Jokaji H, Saito M, Kumabashiri I, Uotami C, et al. Prothrombin fragment F1. + 2 and thrombin-antithrombin III complex are useful markers of the hypercoagulable state in atrial fibrillation. Blood Coagul Fibrinolysis. 1992:3:469-73.
73. Lip GY, Rumley A, Dünn FG, Löwe GD. Plasma fibrinogen and fibrin D-dimer levels in patients with atrial fibrillation: effects of cardioversion to sinus rhythm. Int J Cardiol. 1995;51:245-51.
74. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA. 1998;280:605-13.
75. Feinberg WM, Pearce LA, Hart RG, Cushman M, Cornell ES, Lip GY, et al. Markers of thrombin and platelet activity in patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III Study. Stroke. [In press].
76. Van Gelder IC, Crijins HJ, Blanksma PK, Landsman ML. Posma JL, Van Den Berg MP, et al. Time course of hemodynamic changes and improvement of exercise tolerance after cardioversion of chronic atrial fibrillation unassociated with cardiac valve disease. Am J Cardiol. 1993;72:560-6.
77. Petersen P, Kastrup J. Videbaek R, Boysen G. Cerebral blood flow before and after cardioversion of atrial fibrillation. J Cereb Blood Flow Metab. 1989; 9:422-5.
78. Catherwood E, Fitzpatrick WD, Greenberg ML, Holzberger PT, Malenka DJ, Gerling BR, et al. Cost-effectiveness of cardioversion and antiarrhythmic therapy in nonvalvular atrial fibrillation. Ann Intern Med. 1999; 130;625-36.
79. Van Gelder IC, Crijins HJ, Tieleman RG, Brugemann J, De Kam PJ, Gosselink AT, et al. Chronic atrial fibrillation. Success of serial cardioversion therapy and safety of oral anticoagulation. Arch Intern Med. 1996; 156:2585-92.
80. Kowey PR, Marinchak RA, Rials SJ, Heaney S, Bharucha DB. Atrial fibrillation trials: will they teach us what we need to know? Am J Cardiol. 1998;82:86N-91N.